• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Technology Events 2025-2026
  • Sponsored Post
    • Make a Contribution
  • Technology Jobs
  • Technology Markets
  • About
    • GDPR
  • Contact

Moderna Announces the European Commission’s Approval of Advance Purchase Agreement for Initial 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

November 25, 2020 By admin Leave a Comment

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Commission has approved an agreement to secure 80 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, as part of the European Commission’s goal to secure access to a safe and effective COVID-19 vaccine for Europe.

Under the terms of the proposed agreement, the European Commission has the option to increase their purchase of mRNA-1273, from 80 million doses to a total of up to 160 million doses. The agreement will be finalized following a brief review period by the European Union Member States. This announcement follows the conclusion of advanced exploratory talks with the European Commission that began on August 24, 2020. Delivery of the vaccine could begin as early as the first quarter 2021 if it is approved for use by the European Medicines Agency (EMA) human medicines committee (CHMP), which started a rolling review of mRNA-1273 on November 17.

“We appreciate the confidence the European Commission has demonstrated in our mRNA vaccine platform by including mRNA-1273 in their portfolio of vaccines. We recognize that tackling this global pandemic will require a number of solutions, and we are proud of the role Moderna has been able to play in this global effort,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We have scaled up our manufacturing capacity outside of the United States with our strategic partners, Lonza and Rovi, to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year beginning in 2021, if approved.”

In Europe, Moderna is working with its strategic manufacturing partners, Lonza of Switzerland and ROVI of Spain, for manufacturing and fill-finish outside of the United States. This is a dedicated supply chain to support Europe and countries other than the United States that enter into purchase agreements with Moderna. The Company remains on track to manufacture 500 million to 1 billion doses globally in 2021. If the relevant regulatory approvals are granted, Moderna expects to begin shipping mRNA-1273 to the European Union beginning in December 2020.

On November 16, Moderna announced that the independent, U.S. NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273 has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

Filed Under: Tech

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • Unify Raises $40M to Redefine Go-To-Market with AI Agents That Scale Sales
  • Seagate Unleashes 30TB Hard Drives to Fuel AI Infrastructure at the Edge
  • Firefly Takes Flight: Adobe’s Mobile Expansion Sparks New Growth Horizon
  • SkyDrive’s ¥8.3 Billion Pre-Series D Raise Anchors Japan’s Air Mobility Future
  • HPE and Juniper: A Strategic Fusion at the Core of AI-Native Networking
  • Adobe Inc. Analysis Report: Navigating Uncertainty with Resilience
  • NOS: A New Reactor for American Nuclear Ambition
  • Adobe Introduces LLM Optimizer to Help Brands Navigate the Generative AI Shift
  • Why Visa and Mastercard Stocks Slipped After the Stablecoin News
  • iOS 26: The Most Personal, Intelligent, and Private iPhone Experience Yet

Media Partners

  • Market Analysis
  • Cybersecurity Market
EU Blinks First: Temporary Suspension of Tariff Countermeasures Signals Strategic Caution in U.S. Trade Conflict
AMD Set to Surge: $250 Target Within Reach as AI Momentum Accelerates
China’s Strategic Shift to RISC-V: Market Implications and Growth Prospects
Understanding Transfer Pricing: A Key Component of Multinational Business Operations
A Comprehensive Tour of Project Management Tools and Integration Platforms
Implementing Odoo ERP in a Small Manufacturing Enterprise: Costs and Considerations
Economic Optimism Meets Uncertainty: Blue Chip Indicators Highlight Post-Election Fiscal Concerns and AI’s Looming Impact
The Future of Connectivity: Insights from Ericsson’s November 2024 Mobility Report
Platinum Market Faces Sustained Deficit Amidst Strong Demand and Constrained Supply
Breaking Beijing’s Grip: U.S. and Australia Unite Against China’s Rare Earth Monopoly
SquareX Collaborates with Top Fortune 500 CISOs to Launch The Browser Security Field Manual at Black Hat
CrowdStrike Deepens AWS Partnership to Drive Secure AI Adoption and Innovation
CyberArk Expands Identity Security with Secure Cloud Access and Agent Guard in AWS Marketplace AI Category
CyberBay2025: Forging the Future of Digital Defense, October 13–15 2025, Tampa Marriott Water Street
GitGuardian Launches MCP Server to Bring Secrets Security into Developer Workflows
Stellar Cyber 6.0.0: Ushering in the Human-Augmented Autonomous SOC
MITRE Unveils AADAPT Framework to Safeguard Digital Financial Systems
Cogent Security Emerges from Stealth to Tackle the Fastest-Growing Threat in Cybersecurity with AI-Powered Vulnerability Management
Cyber’s Leading Minds Take the Stage at Black Hat USA 2025
INE Security Launches Enhanced eMAPT Certification

Media Partners

  • Market Research Media
  • Technology Conferences
Adobe Set to Hit $640: AI Growth and Financial Strength Signal Imminent Breakout
The Rise of Headless Content Frameworks in Distributed Media Projects
Developing Web Projects: From Concept to Launch
The Rise of APS-C Cameras: A Professional Renaissance in Photography
Market Brief: Disruption in Spanish Orange Supply Chain and Strategic Response by UK Retailers
Global AI-Powered Movie Scenario Market Analysis 2023-2030: Growth, Trends, and Forecast
Market Research Report: US Government Cybersecurity Market in 2024
Market Research Report: Global Advertising Revenue Projections and Trends in the Entertainment & Media Industry
Social Media: The Rise of Formulaic Content
Netflix’s Creative Decline: The Rise of Formulaic Content
Apple Announces WWDC25, June 9 to 13, 2025
Adobe Summit 2025, March 17-20, Las Vegas
Embedded World 2025, from 11 to 13 March 2025 in Nuremberg
SATELLITE 2025: Uniting the Global Satellite and Space Communities
The milestone 10th edition of Chatbot Summit on March 31 – April 1, 2025, The Ritz-Carlton, Berlin
Snowflake Summit 2025, scheduled for June 2-5, 2025, in San Francisco
The NVIDIA GPU Technology Conference (GTC) 2025 is set to take place from March 17 to 21 at the San Jose McEnery Convention Center in San Jose, California
The Taipei Nangang Exhibition Center is set to host COMPUTEX 2025 from May 20 to May 23
The Mobile World Congress (MWC 2025) will kick off from March 3 to 6 in Barcelona, Spain
IOT Solutions World Congress 2025: Forging the Future of Industrial Innovation

Copyright © 2022 Technologies.org

Media Partners: Market Analysis & Market Research and Exclusive Domains